| First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. L Lupinacci, C Martin, N Pilnik, ME Richardet, MS Varela, J Adams, ... N Engl J Med 376 (25), 2415-2426, 2017 | 2662* | 2017 |
| Inflammation and cancer: causes and consequences MM Moore, W Chua, KA Charles, SJ Clarke Clinical Pharmacology & Therapeutics 87 (4), 504-508, 2010 | 297 | 2010 |
| Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice M Tsoli, M Moore, D Burg, A Painter, R Taylor, SH Lockie, N Turner, ... Cancer research 72 (17), 4372-4382, 2012 | 190 | 2012 |
| A randomized controlled trial of a wearable technology‐based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer … BM Lynch, NH Nguyen, MM Moore, MM Reeves, DE Rosenberg, T Boyle, ... Cancer 125 (16), 2846-2855, 2019 | 157 | 2019 |
| Ethnic differences in drug metabolism and toxicity from chemotherapy VH Phan, MM Moore, AJ McLachlan, M Piquette-Miller, H Xu, SJ Clarke Expert opinion on drug metabolism & toxicology 5 (3), 243-257, 2009 | 140 | 2009 |
| A qualitative evaluation of breast cancer survivors’ acceptance of and preferences for consumer wearable technology activity trackers NH Nguyen, NT Hadgraft, MM Moore, DE Rosenberg, C Lynch, ... Supportive Care in Cancer 25 (11), 3375-3384, 2017 | 128 | 2017 |
| Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting AMY Shum, T Mahendradatta, RJ Taylor, AB Painter, MM Moore, M Tsoli, ... Aging (Albany NY) 4 (2), 133, 2012 | 109 | 2012 |
| Use of inflammatory markers to guide cancer treatment SJ Clarke, W Chua, M Moore, S Kao, V Phan, C Tan, K Charles, ... Clinical Pharmacology & Therapeutics 90 (3), 475-478, 2011 | 93 | 2011 |
| Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer W Chua, PS Kho, MM Moore, KA Charles, SJ Clarke Critical reviews in oncology/hematology 79 (3), 224-250, 2011 | 62 | 2011 |
| Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer MM Moore, JM Beith Medical Journal of Australia 188 (6), 370, 2008 | 46 | 2008 |
| A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group MM Moore, M Stockler, R Lim, TSK Mok, M Millward, MJ Boyer Cancer chemotherapy and pharmacology 66 (5), 845-850, 2010 | 41 | 2010 |
| Maintenance of physical activity and sedentary behavior change, and physical activity and sedentary behavior change after an abridged intervention: Secondary outcomes from the … BM Lynch, NH Nguyen, MM Moore, MM Reeves, DE Rosenberg, T Boyle, ... Cancer 125 (16), 2856-2860, 2019 | 38 | 2019 |
| Linking physical activity to breast cancer via sex steroid hormones, part 2: The effect of sex steroid hormones on breast cancer risk AE Drummond, CTV Swain, KA Brown, SC Dixon-Suen, L Boing, ... Cancer Epidemiology and Prevention Biomarkers 31 (1), 28-37, 2022 | 37 | 2022 |
| Effects of a wearable technology-based physical activity intervention on sleep quality in breast cancer survivors: The ACTIVATE Trial NH Nguyen, JK Vallance, MP Buman, MM Moore, MM Reeves, ... Journal of Cancer Survivorship 15 (2), 273-280, 2021 | 35 | 2021 |
| The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma TD Clay, H Do, V Sundararajan, MM Moore, M Conron, GM Wright, ... Journal of thoracic oncology 9 (5), 654-663, 2014 | 31 | 2014 |
| Effects of the ACTIVity And TEchnology (ACTIVATE) intervention on health‐related quality of life and fatigue outcomes in breast cancer survivors JK Vallance, NH Nguyen, MM Moore, MM Reeves, DE Rosenberg, ... Psycho‐oncology 29 (1), 204-211, 2020 | 28 | 2020 |
| Linking Physical Activity to Breast Cancer via Sex Hormones, Part 1: The Effect of Physical Activity on Sex Steroid Hormones CTV Swain, AE Drummond, L Boing, RL Milne, DR English, KA Brown, ... Cancer Epidemiology and Prevention Biomarkers 31 (1), 16-27, 2022 | 26 | 2022 |
| Study design and methods for the ACTIVity And TEchnology (ACTIVATE) trial BM Lynch, NH Nguyen, MM Reeves, MM Moore, DE Rosenberg, ... Contemporary clinical trials 64, 112-117, 2018 | 22 | 2018 |
| Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations TD Clay, PA Russell, H Do, V Sundararajan, M Conron, GM Wright, ... Pathology 48 (1), 17-24, 2016 | 17 | 2016 |
| Assessment and relevance of enzyme‐linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease MM Moore, D Fabricatorian, WS Selby Internal medicine journal 32 (7), 349-352, 2002 | 17 | 2002 |
